Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone
Drug ID BADD_D00623
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage Dexamethasone and [ciprofloxacin] otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa.[L10698] Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Oral tablets are indicated for the treatment of multiple myeloma.[L10710] An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye.[L10719] Various ophthalmic formulations are indicated for inflammatory conditions of the eye.[L10704,L10707,L10713,L10716,L10722,L10725]
Marketing Status approved; investigational; vet_approved
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D00292
MeSH ID D003907
PubChem ID 5743
TTD Drug ID D0IT2G
NDC Product Code 80425-0328; 0009-5019; 22552-0039; 38779-0405; 0904-7266; 55154-4901; 63187-561; 67296-1496; 70518-2998; 70868-920; 0054-4183; 0054-8176; 0054-8181; 0054-8183; 0998-0615; 55718-133; 71161-138; 79572-012; 42195-490; 45865-989; 55154-4914; 68788-8223; 70382-204; 71205-012; 42291-155; 50090-0088; 60687-718; 60687-729; 64980-509; 68788-8467; 72189-383; 55289-582; 60219-2044; 67296-0326; 0054-4179; 0054-8179; 0054-8180; 72893-015; 55718-157; 65089-0045; 42195-127; 60219-2043; 63629-7850; 70954-402; 71205-013; 0054-4181; 0054-4182; 0054-4186; 71205-703; 71879-001; 46439-8765; 82298-111; 50090-6151; 61919-827; 63187-383; 63629-4129; 63629-7806; 68788-7267; 69306-111; 69306-114; 70518-3050; 70954-404; 0054-4184; 49452-2465; 0078-0925; 0023-3348; 61919-269; 68071-2744; 68788-8293; 0054-3177; 70954-403; 0054-8175; 71335-2108; 72189-254; 51552-0430; 51927-1081; 52128-170; 42195-721; 43063-266; 48102-051; 50090-0089; 54879-003; 60219-2056; 62135-114; 68788-7142; 70954-401; 0054-8174; 72189-468; 60722-3013; 0121-1814; 42195-121; 42195-149; 42195-221; 47781-914; 47781-916; 55700-961; 69306-112; 55289-903; 63629-3742; 66993-730; 67296-1837; 68071-2321; 0054-4180; 55718-156; 57582-031; 57582-931; 42195-270; 50090-6152; 51407-361
UNII 7S5I7G3JQL
Synonyms Dexamethasone | Methylfluorprednisolone | Hexadecadrol | Decameth | Decaspray | Dexasone | Dexpak | Maxidex | Millicorten | Oradexon | Decaject | Decaject-L.A. | Decaject L.A. | Hexadrol
Chemical Information
Molecular Formula C22H29FO5
CAS Registry Number 50-02-2
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug resistance08.06.01.0050.001526%Not Available
Hyperinsulinaemia14.06.03.005; 05.06.03.0050.000218%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Neurological symptom17.02.05.0100.000291%Not Available
Skin test negative13.06.04.002--Not Available
Embolism24.01.01.0090.000436%
Haematotoxicity12.03.01.025; 01.05.01.0070.000581%Not Available
Lipid metabolism disorder14.08.04.003--Not Available
Iris disorder06.06.06.0050.001497%Not Available
Ischaemia24.04.02.0040.000145%Not Available
Mental disorder19.07.01.002--Not Available
Metastatic neoplasm16.16.01.0070.000145%Not Available
Motor dysfunction17.01.02.031; 15.05.06.0060.000145%Not Available
Optic neuropathy06.02.08.002; 17.04.05.0050.000145%Not Available
Partial seizures17.12.03.0100.000436%Not Available
Perineal pain21.10.01.0030.000145%
Abnormal behaviour19.01.01.0010.001017%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Corneal disorder06.08.01.0040.001308%Not Available
Scleral disorder06.09.06.0020.000218%
Ill-defined disorder08.01.03.049--Not Available
Mitral valve disease02.07.01.0030.000145%
Red blood cell abnormality01.07.02.0060.000320%Not Available
Sensation of foreign body08.01.09.002--Not Available
Blood disorder01.05.01.0040.000218%Not Available
Bone lesion15.02.04.0160.000363%Not Available
Disease progression08.01.03.0380.003444%
Disease recurrence08.01.03.0500.001090%Not Available
Diverticular perforation07.04.04.0080.000145%Not Available
Neoplasm recurrence16.16.02.0040.000145%Not Available
The 21th Page    First    Pre   21 22 23 24 25    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene